Conclusion: Treatment with liraglutide is safe and improves critical features of PD, including non-motor symptoms, overall mobility, activities of daily living, and quality of life
Color blindness Eye Injury occurred within a time span of about a month
The fact that both cagrilintide and semaglutide have ~7-day half-lives is what makes CagriSema possible as a single weekly research protocol
Trulicity belongs to a class of medications called GLP-1 receptor agonists, which also includes semaglutide (Ozempic and Wegovy), liraglutide (Victoza and Saxenda), and tirzepatide (Zepbound and Mounjaro)
Later, it was approved for use in individuals with a body mass index (BMI) of 27 or above weight gain and those with at least one weight-related health problem, such as high blood pressure or type 2 diabetes, to promote weight loss